Atara Biotherapeutics & United States — Food and Drug Administration

Atara Biotherapeutics: Atara Biotherapeutics is the defendant in a class action lawsuit alleging false and misleading statements regarding its business, operations, and prospects, specifically concerning the regulatory approval of its lead product candidate, tabelecleucel. Its stock price experienced significant declines following FDA decisions.

United States — Food and Drug Administration: The United States — Food and Drug Administration issued Complete Response Letters and placed a clinical hold on Atara Biotherapeutics' Investigational New Drug applications, citing manufacturing issues and deficiencies in the ALLELE study, which directly impacted the company's stock price and led to the class action.

Atara Biotherapeutics: Atara Biotherapeutics is the defendant in a class action lawsuit alleging misleading statements regarding its tabelecleucel Biologics License Application and manufacturing issues. This event negatively impacts its stock price and reputation.

United States — Food and Drug Administration: The United States — Food and Drug Administration's potential non-approval of tabelecleucel's Biologics License Application due to manufacturing issues is a key factor in the lawsuit against Atara Biotherapeutics.

Atara Biotherapeutics: Atara Biotherapeutics is the defendant in a securities fraud class action lawsuit, facing allegations of misleading investors about manufacturing issues and regulatory prospects of its drug tabelecleucel.

United States — Food and Drug Administration: The United States — Food and Drug Administration's potential non-approval of tabelecleucel BLA due to manufacturing issues and study deficiencies is a central point of the lawsuit against Atara Biotherapeutics.

Atara Biotherapeutics: Atara Biotherapeutics is the defendant in a class action lawsuit for allegedly making false and misleading statements regarding its manufacturing processes and the prospects of its drug tabelecleucel, leading to investor losses.

United States — Food and Drug Administration: The United States — Food and Drug Administration's potential non-approval of Atara Biotherapeutics' BLA for tabelecleucel due to manufacturing problems and study deficiencies is a key point in the lawsuit.